sacituzumab govitecan

targets

all catalysts(1)

News(10)

• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
  The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
  biopharma_dive · 23d ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 28d ago
• CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
  Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…
  fiercebiotech · 29d ago
• Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
  Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. Th…
  fiercebiotech · 1mo ago
• Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
  Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
  biopharma_dive · 4mo ago
• Gilead and Merck’s latest trial success and flop
  AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
  stat · 4mo ago
• Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
  Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The pa…
  endpoints · 4mo ago
• At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
  Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
  biopharma_dive · 4mo ago
• Merck ADC, licensed from China, hits mark in first big global trial
  The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
  biopharma_dive · 4mo ago
• Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
  Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
  onclive · 4mo ago